Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR1F | P30939 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861475 | 0.90 | ABL1 (0.56) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12345959 | 0.87 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL7026694 | 0.84 | ABL1 (0.41) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL13722092 | 0.84 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL10072470 | 0.82 | ABL1 (0.51) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL12408886 | 0.82 | ABL1 (0.51) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL4773361 | 0.82 | P2RY6 (0.42) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL25629925 | 0.81 | ABL1 (0.52) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL13607347 | 0.81 | ABL1 (0.50) | ABL1RIN1P2RY6P2RY14NT5E | |
| SCHEMBL4778644 | 0.80 | ABL1 (0.45) | ABL1RIN1P2RY6P2RY14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | ABL1 3017/4885RIN1 1196/4885P2RY6 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.